Skip to main content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.
Diabetes
- Comparing metformin and glyburide in a combination medication as well as monotherapy in the treatment of diabetes mellitus type II
- Comparing exenatide versus insulin glargine in the treatment of diabetes mellitus type II
- Comparing insulin glulisine vs. insulin lispro for treating type II diabetes
- Rosiglitazone vs. pioglitazone for treating type II diabetes
- Rosiglitazone vs. pioglitazone for diabetic patients at risk for coronary heart disease
- Rosiglitazone vs. insulin for diabetic patients at risk for coronary heart disease
- Pioglitazone vs. insulin for diabetic patients at risk for coronary heart disease
- Liraglutide vs. glimepiride to treat type II diabetes
- Metformin vs. Actos for treating diabetes
- Comparing liraglutide to exenatide for treating type II diabetes
- Diet and exercise versus pioglitazone for treating obesity
- Insulin glulisine vs. insulin lispro for treating diabetes
- Comparing metformin to sulfonylureas: cardiovascular and all-cause mortality
- Metformin and glimepiride vs. metformin and empagliflozin for treating type 2 diabetes
- Exenatide vs. glimepiride for treating type 2 diabetes
- Vildagliptin versus metformin for treating type 2 diabetes
Osteoporosis
- Alendronate vs. risedronate for treating osteoporosis
- Teriparatide and denosumab versus teriparatide alone for treating osteoporosis
- Teriparatide and denosumab versus denosumab alone for treating osteoporosis
- Ibandronate versus risedronate for treating osteoporosis
- Romosozumab versus alendronate for preventing fractures in women with osteoporosis
- Ibandronate versus alendronate for treating osteoporosis
